{
  "query": "AMGN",
  "resolved": {
    "ticker": "AMGN",
    "cik": "0000318154",
    "title": "AMGEN INC"
  },
  "signals": [
    {
      "type": "trial_to_filing",
      "headline": "AMGEN INC (AMGN) — PHASE3 protocol updated 3 days ago",
      "entity": "Amgen",
      "ticker": "AMGN",
      "cik": "0000318154",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer",
        "nctId": "NCT07213674",
        "date": "2030-01-07"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT07213674"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07213674",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "AMGEN INC (AMGN) — PHASE3 protocol updated 3 days ago",
      "entity": "Amgen",
      "ticker": "AMGN",
      "cik": "0000318154",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE3)",
        "detail": "Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity",
        "nctId": "NCT07037433",
        "date": "2028-06-30"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT07037433"
      },
      "predicted": {
        "event": "SEC 8-K / press release on NDA/BLA filing (FDA submission)",
        "leadTime": "12-24 mo",
        "baseRate": 0.58,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 57% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07037433",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154&type=8-K"
      }
    },
    {
      "type": "trial_to_filing",
      "headline": "AMGEN INC (AMGN) — PHASE2 protocol updated 3 days ago",
      "entity": "Amgen",
      "ticker": "AMGN",
      "cik": "0000318154",
      "tickerConfidence": 0.95,
      "upstream": {
        "event": "Clinical trial status (PHASE2)",
        "detail": "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight",
        "nctId": "NCT07441252",
        "date": "2027-09-29"
      },
      "observed": {
        "event": "protocol updated 3 days ago",
        "nctId": "NCT07441252"
      },
      "predicted": {
        "event": "SEC 8-K / press release on Phase 3 initiation",
        "leadTime": "18-36 mo",
        "baseRate": 0.29,
        "note": "Reg FD requires prompt disclosure of material clinical results."
      },
      "leadTime": "Phase-transition base rate 28% (Wong/Siah/Lo 2019)",
      "confidence": 0.35,
      "links": {
        "trial": "https://clinicaltrials.gov/study/NCT07441252",
        "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000318154&type=8-K"
      }
    }
  ],
  "recentFilings": {
    "name": "AMGEN INC",
    "sicDescription": "Biological Products, (No Diagnostic Substances)",
    "filings": [
      {
        "form": "8-K",
        "date": "2026-05-20",
        "accession": "0001193125-26-232786",
        "items": "5.07"
      },
      {
        "form": "8-K",
        "date": "2026-05-19",
        "accession": "0000318154-26-000097",
        "items": "5.02"
      },
      {
        "form": "8-K",
        "date": "2026-04-30",
        "accession": "0000318154-26-000054",
        "items": "2.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-04-22",
        "accession": "0000318154-26-000048",
        "items": "5.02,9.01"
      },
      {
        "form": "8-K",
        "date": "2026-02-19",
        "accession": "0001193125-26-059490",
        "items": "1.01,9.01"
      }
    ]
  },
  "disclaimer": "Research/informational. NOT investment advice.",
  "generatedAt": "2026-06-21T09:50:25.029Z"
}